Analysts think GlaxoSmithKline is fairly priced

GlaxoSmithKline 's stock price seems, partly because of the recent share price losses, to be in line with most of the estimates. Most of the analysts say GlaxoSmithKline is fairly priced now. Currently the company is being followed by 20 analysts. The average of the current target prices for the stock equals 1473,39 GBp. This is at around 2 percent less than the current price of 1502,4 GBp.

Estimates for GlaxoSmithKline not very concentrated

stock price

Over the current book year the total revenue will be 30,45 billion GBp (consensus estimates). This is slightly more than 2017's revenue of 30,19 billion GBp.

Historical revenues and results GlaxoSmithKline plus estimates 2018

fundamental data

The analysts expect for 2018 a net profit of 5,63 billion GBp. According to most of the analysts the company will have a profit per share for this book year of 113 GBp. Based on this the price/earnings-ratio is 13,3.

Huge dividend GlaxoSmithKline

Analysts expect a dividend of 80 GBp per share. GlaxoSmithKline 's dividend yield thus equals 5,32 percent. The average dividend yield of the pharmaceutical companies equals a limited 0,5 percent.

Latest estimates around 1475 GBp

Societe Generale , Jefferies & Co. and Liberum recently provided recommendations for the stock.

Based on the current number of shares GlaxoSmithKline 's market capitalization equals 7376,95 billion GBp. The GlaxoSmithKline stock was the past 12 months quite unstable. Since last November the stock is 17 percent higher. This year the stock price moved between 1235 and 1634 GBp. Since 2008 the stock price is almost 30 percent higher.

Historical stock prices GlaxoSmithKline

fundamental data glaxosmithkline

At 17.53 the stock trades 0,32 percent lower at 1502,4 GBp.

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.